188 related articles for article (PubMed ID: 35910942)
21. Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.
Konkle BA; Oldenburg J; Pasi J; Kulkarni R; Nolan B; Mahlangu J; Young G; Brown SA; Pabinger I; Shapiro A; Négrier C; Blanchette V; Ragni MV; Dumont J; Lethagen S
Res Pract Thromb Haemost; 2023 Aug; 7(6):102180. PubMed ID: 37753224
[TBL] [Abstract][Full Text] [Related]
22. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.
Nolan B; Mahlangu J; Pabinger I; Young G; Konkle BA; Barnes C; Nogami K; Santagostino E; Pasi KJ; Khoo L; Winding B; Yuan H; Fruebis J; Rudin D; Oldenburg J
Haemophilia; 2020 May; 26(3):494-502. PubMed ID: 32227570
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
[TBL] [Abstract][Full Text] [Related]
24. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
[TBL] [Abstract][Full Text] [Related]
25. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
Haemophilia; 2021 Sep; 27(5):751-759. PubMed ID: 34160870
[TBL] [Abstract][Full Text] [Related]
26. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.
Shapiro A
Expert Opin Biol Ther; 2013 Sep; 13(9):1287-97. PubMed ID: 23930915
[TBL] [Abstract][Full Text] [Related]
27. Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data.
Farahbakhshian S; Fan Q; Schultz BG; Princic N; Park J; Bullano M
J Med Econ; 2023; 26(1):1278-1286. PubMed ID: 37787429
[TBL] [Abstract][Full Text] [Related]
28. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
[TBL] [Abstract][Full Text] [Related]
29. Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery.
Désage S; Nougier C; Meunier S; Chamouard V; Jousselme E; Dargaud Y; Lienhart A
Haemophilia; 2024 Mar; 30(2):538-544. PubMed ID: 38149726
[TBL] [Abstract][Full Text] [Related]
30. A survey of physicians' treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries.
van der Sluijs M; Huyghe N; Wood C; Tawil S
Curr Med Res Opin; 2022 Jan; 38(1):65-73. PubMed ID: 34634979
[TBL] [Abstract][Full Text] [Related]
31. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
[TBL] [Abstract][Full Text] [Related]
32. Recombinant factor IX Fc for the treatment of hemophilia B.
Ljung R; Matino D; Shapiro AD
Eur J Haematol; 2024 May; 112(5):678-691. PubMed ID: 38369860
[TBL] [Abstract][Full Text] [Related]
33. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.
Mancuso ME; Mannucci PM
Drug Des Devel Ther; 2014; 8():365-71. PubMed ID: 24729686
[TBL] [Abstract][Full Text] [Related]
34. The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B.
Sun HL; Yang M; Poon MC; Lee A; Robinson KS; Sholzberg M; Wu J; Iorio A; Blanchette V; Carcao M; Klaassen RJ; Jackson S
Res Pract Thromb Haemost; 2021 Oct; 5(7):e12601. PubMed ID: 34667922
[TBL] [Abstract][Full Text] [Related]
35. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
Mahlangu J; Powell JS; Ragni MV; Chowdary P; Josephson NC; Pabinger I; Hanabusa H; Gupta N; Kulkarni R; Fogarty P; Perry D; Shapiro A; Pasi KJ; Apte S; Nestorov I; Jiang H; Li S; Neelakantan S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Dodd N; Nugent K; Vigliani G; Luk A; Brennan A; Pierce GF;
Blood; 2014 Jan; 123(3):317-25. PubMed ID: 24227821
[TBL] [Abstract][Full Text] [Related]
36. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.
Nolan B; Klukowska A; Shapiro A; Rauch A; Recht M; Ragni M; Curtin J; Gunawardena S; Mukhopadhyay S; Jayawardene D; Winding B; Fischer K; Liesner R
Blood Adv; 2021 Jul; 5(13):2732-2739. PubMed ID: 34242387
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
[TBL] [Abstract][Full Text] [Related]
38. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.
Dumont JA; Liu T; Low SC; Zhang X; Kamphaus G; Sakorafas P; Fraley C; Drager D; Reidy T; McCue J; Franck HW; Merricks EP; Nichols TC; Bitonti AJ; Pierce GF; Jiang H
Blood; 2012 Mar; 119(13):3024-30. PubMed ID: 22246033
[TBL] [Abstract][Full Text] [Related]
39. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
[TBL] [Abstract][Full Text] [Related]
40. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.
Wang M; Álvarez-Román MT; Chowdary P; Quon DV; Schafer K
Blood Coagul Fibrinolysis; 2016 Oct; 27(7):737-744. PubMed ID: 27116081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
